Scroll down
According to the China Food and Drug Administration regulation No. 24, which announced the "Drug Instruction and Labeling Regulations", after the drug instruction is approved for revision, the drug manufacturer shall immediately notify the relevant drug business enterprises, user units and other departments of the revised content. In order to enable the relevant units and medical & health professionals to obtain the latest information on the instructions in a timely manner, our company is required to publish the latest approved information on the instructions.
(Only listed products in mainland China)
No.99, Shanshui Road, Dianbu Town, Feidong County, Hefei, Anhui, China
Eberson Pharmaceuticals Co., Ltd.
No.69, Shanshui Road, Dianbu Town, Feidong County, Hefei, Anhui, China
601-603/6F, Fortune Financial Center 5 Dong San Huan Central Road Chaoyang District, Beijing, China
22nd Floor, New Bund Shun Tak Center No. 18, Lane 666, Hai Yang West Road, Pudong New Area, SHANGHAI 200026
Room 3301-3302, China International Center Tower B, No. 33 Zhongshan Third Road Yuexiu, Guangzhou, China
20th Floor, #G Build, Huanglong International Center Tower, No.77, Xueyuan Road, West Lake District, Hangzhou, Zhejiang, China
公司地址：这里是公司地址后期需要替换设计占位后台可替换
企业邮箱：infu@singlera.com.cn
联系电话：+86-8888-8888
商务联系：BD@singlera.com.cn
人力资源：HR@singlera.com.cn
